Other Clinical Trial - Pan-Cardio-Genetics Clot Assessment in Acute

Status Withdrawn

Clinical Trial Summary

Acute myocardial infarction with ST elevation (STEMI) is one of the leading causes of mortality. Although the presence of thrombus in STEMI patients has been linked to adverse outcomes, routine thrombus aspiration has not been proven effective. A potential explanation could be that patients with STEMI should be risk-stratified. Thus, a more personalized approach in treating these patients is stressfully required. This proposal aims to establish the required interdisciplinary infrastructure for developing a risk-stratification model by implementing clinical, laboratory and angiographic data with molecular knowledge obtained by using innovative technologies, such as data from nano/micro-Computed tomography and circulating microRNAs. Two hundred consecutive patients with STEMI undergoing thrombus aspiration will be enrolled in the study and will be followed-up for one year for Major Adverse Cardiac and Cerebrovascular events (MACCE). The proposed approach will shed light on the pathophysiological mechanisms and broaden the investigator's understanding of the complex cellular and molecular interactions in the STEMI setting that, along with clinical parameters, affect patient outcomes. Furthermore, it will enable the identification of certain circulating micro-RNAs as cardiovascular disease biomarkers and it will help clinicians to better stratify the cardiovascular and cerebrovascular risk of patients with STEMI. As part of the work, important characteristics of aspirated thrombi will be assessed for the first time (such as volume, density and shape) and will be linked to patient outcomes. All this information will be incorporated into one in-vitro model, which will be developed using bioprinting and microfluidics methodologies. The in-vitro model will facilitate: (i) the in-depth exploration of the pathophysiological mechanisms in patients with STEMI; and (ii) the therapeutic optimization of innovative nanocarriers/nanomedicines with thrombolytic efficacy. Clearly, the study improves personalized cardiovascular medicine approaches, by considering individual patient clinical assessment in a way that empowers the precision in diagnosis and therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acute Coronary Syndrome
Infarction
MicroRNA
Myocardial Infarction
ST Elevation Myocardial Infarction
STEMI - ST Elevation Myocardial Infarction
Thrombi
Thrombosis

Clinical Trial Details

NCT number	NCT03832153
Study type	Observational
Source	Aristotle University Of Thessaloniki
Contact
Status	Withdrawn
Phase
Start date	January 20, 2019
Completion date	March 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06013813` - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI	N/A
Terminated	`NCT04542889` - Coronary Microcirculation Assessment After Primary Angioplasty in Myocardial Infarction	N/A
Recruiting	`NCT04951856` - Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI	Phase 4
Terminated	`NCT04459299` - CorPath GRX STEMI Study
Recruiting	`NCT05557019` - Semi Occlusion of the Coronary Sinus as an Adjunct to PCI in STEMI Patients, FIH Clinical Study	N/A
Completed	`NCT03527940` - Prognostic Markers of Patients With STEMI
Not yet recruiting	`NCT03264859` - NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction	N/A
Not yet recruiting	`NCT03182855` - Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI	Phase 4
Not yet recruiting	`NCT03266289` - Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab	N/A
Withdrawn	`NCT04566289` - Observational Registry to Evaluate Real World Usage of PiCSO Impulse System in STEMI Patients as Part of Post-marketing Surveillance
Completed	`NCT04289012` - HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study	N/A
Not yet recruiting	`NCT04185077` - Bivalirudin in Late PCI for Oatients With STEMI	Phase 4
Completed	`NCT03609346` - Asian Registry of the BioFreedom Stent for STEMI Patients
Recruiting	`NCT05107076` - Effect of PPCI on Diastolic Function & Levels of Galactin-3 in Patients With STEMI
Recruiting	`NCT02998853` - Non Culprit Functional Evaluation With 3D Angio QFR in STEMI PCI Procedure	N/A
Completed	`NCT03677180` - National Cardiogenic Shock Initiative
Completed	`NCT03507777` - ILUMIEN IV: OPTIMAL PCI	N/A
Recruiting	`NCT03863327` - EKG Criteria and Identification of Acute Coronary Occlusion
Completed	`NCT03070496` - Multicenter Cohort of STEMI Patients	N/A
Active, not recruiting	`NCT03874338` - CLEAR SYNERGY Neutrophil Substudy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pan-Cardio-Genetics Clot Assessment in Acute Coronary Syndromes — PGCA-ACS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms